. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Ann Allergy Asthma Immunol. 2017 Sep;119(3):238–245. doi: 10.1016/j.anai.2017.06.018

Table 1.

Sample characteristics (n= 196)

Demographic variable
Child age in years, M (SD)	8.31 (.87)
Male (%)	53
Caregiver race/ethnicity (%)
Black	34
Latino	51
Non-Latino White	15
At/below poverty threshold (%)	70
Number of people in household, M (SD)	4.70 (1.76)
Asthma Severity (%)
Mild persistent	56
Moderate persistent	33
Severe persistent	11
Asthma poorly controlled (%)	44
Asthma medications (%)
Inhaled corticosteroid	70
Long-acting beta agonists	5
AR medications (%)
Intranasal steroid	11
Antihistamine use (%)
1^st generation antihistamine	18
2^nd generation antihistamine	26
FEV₁% predicted, M (SD)	83.9 (12.80)
Variability in FEV₁% predicted, M (SD)	14.97 (5.96)
Risk for sleep disordered breathing (%)	49
BMI percentile for age, M (SD)	74.32 (25.22)
Sleep health indicators
Sleep efficiency (%), M (SD)	86.54 (3.48)
Variability in sleep efficiency, M (SD)	4.17 (1.87)
Sleep duration (minutes), M (SD)	554.49 (35.04)
Mean number of awakenings per night, M (SD)	5.35 (2.42)